📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #GeriatricOncology #Oncogeriatrics #CancerCare #MedSky #OncSky #MedNews #Vocabulary
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #CancerAwareness #CancerCare #ParaneoplasticSyndrome #PNS #MedSky #OncSky #Vocabulary
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #MedSky #OncSky #CancerAwareness #InvestigationalNewDrug #IND #FDA #ClinicalTrials #Vocabulary
#lynchsyndrome
#CAPP3
Lynch syndrome carriers face up to 80% lifetime CRC risk! The ongoing CAPP3 trial is exploring optimal aspirin doses for Lynch Syndrome
#Onco404 #Cancer #Kanser #ClinicalTrials #LynchSyndrome #ColorectalCancer #EndometrialCancer #Aspirin #CancerPrevention #MedSky #OncSky
Multi-omics profiling is feasible, accelerates precision oncology, and improves outcomes for advanced melanoma.
#Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025
The TuPro study used 9 #multiomics technologies (scRNA-seq, proteomics, etc.) to profile 116 #melanoma patients, generating >40,000 markers/sample in just 4 weeks.
@natureportfolio.nature.com
#Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #CancerAwareness #CancerCare #Chemokine #ImmuneSystem #ImmuneResponse #TumorImmunity #Vocabulary
☑️ TTF-1 low vs TTF-1 high - ORR: 4.17% vs 42.1% ; mPFS: 2.76 vs 8.11 months (HR 0.23); mOS: 4.47 vs 16 months.
✅ Integration of NRF2 activation status and TTF-1 expression enabled robust partitioning of patients into favorable (~70%), intermediate (~13%) and poor (~17%) prognostic groups.
#Onco404
📊 Key Findings
☑️ KEAP1 co-mutations were correlated with significantly shorter PFS and OS on sotorasib.
✅ NRF2 activation (often linked to KEAP1 mutations) was also associated with inferior outcomes. mPFS: 2.73 vs 7.75 months (NRF2 low)
#Onco404 #Cancer #Kanser #AkciğerKanseri #MedSky #OncSky
This integrated analysis of CodeBreaK 100 & 200 trials delves into biomarkers influencing sotorasib efficacy in KRAS G12C-mutated NSCLC.
#NatureMedicine
#Onco404 #Cancer #Kanser #LungCancer #Sotorasib #NSCLC #Biomarkers #PrecisionOncology #KRAS #TTF1 #KEAP1 #NRF2 #NFE2L2 #MedSky #OncSky
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #Cytokine #ImmuneSystem #CancerCare #Inflammation #MedSky #OncSky #Vocabulary
❌ No significant differences in quality of life, feeling "heard/understood," or late hospice referrals.
✅ This scalable EHR-based strategy addressed clinician barriers, increased PC access without overburdening workflows, and offers a pragmatic solution for resource-limited settings.
#Onco404
📊 Key Findings
✅ 43.9% (intervention) vs. 8.3% (control) completed PC consults (adjusted OR: 8.9) ⤴️
☑️ Systemic therapy within 14 days of death was lower in the intervention group (6.5%) compared to control (16.1%; AOR 0.3).
#Onco404 #Cancer #Kanser #Hospice #PalliativeCare #MedSky #OncSky
A cluster randomized trial tested if algorithm-based EHR defaults with accountable justification could increase specialty palliative care (PC) consultations.
@JAMANetworkOpen #JAMA
#Onco404 #Cancer #Kanser #Hospice #PalliativeCare #SupportiveCare #MedSky #OncSky #Healthcare #DigitalHealth
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #Hospice #YaşamSonuBakımı #PalliativeCare #PalyatifBakım #QoL #MedSky #OncSky #Vocabulary
Timely and comprehensive HRQoL data is vital for integrating patient experiences into clinical and regulatory decision-making.
#Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #FDA #QoL #HRQoL #MedSky #OncSky #PatientReportedOutcomes
📊 HRQoL improved in 43% of trials but worsened in 4%, all linked to SEP-based approvals
⚠️ Reporting hasn’t improved since 2015. Delays mean doctors and patients often wait 6+ months
⚠️ Median latency for reporting was 1.1 months post-approval, but a quarter took over a year
#Onco404 #Cancer #Kanser
📊 Key Findings
📉 50% of trials reported HRQoL data, but only 42% had it available by FDA approval.
📉 79% of approvals relied on surrogate endpoints, yet only 18% of these showed improved HRQoL.
💊 Trials with survival (OS) endpoints: 70% reported HRQoL vs. 45% for SEPs.
#Onco404 #Cancer #Kanser
A new study analyzed 233 trials associated with 207 FDA approvals (2015–2020) and found alarming gaps in health-related quality of life (HRQoL) reporting.
#BMJ #BMJOncology
#Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #FDA #QoL #HRQoL #MedSky #OncSky #PatientReportedOutcomes
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #PatientCenteredCare #CancerCare #QualityOfLife #QoL #PatientReportedOutcomes #PROs #Vocabulary
☑️ Trabectedin showed a higher frequency of grade ≥3 adverse events (AEs), serious AEs, and serious adverse drug reactions.
Trabectedin did not improve survival vs. standard chemo and had a worse safety profile. No subgroup (BRCA status, prior PARPi use) benefited more from trabectedin.
#Onco404
📊 Key Findings
✅ Median overall survival (OS): 15.8 months (arm A: trabectedin) vs. 17.9 months (arm B: control).
☑️ Median progression-free survival (PFS): 4.9 vs. 4.4 months.
✅ ORR was 17.1% (arm A) vs. 21.4% (arm B), with comparable median DoR (5.62 vs. 5.66 months).
#Onco404 #MedSky #OncSky
The phase III MITO-23 trial compared trabectedin monotherapy to physician’s choice chemo in 244 patients with BRCA-mutated or BRCAness recurrent ovarian cancer.
@ascocancer.bsky.social #JCO #ASCO
#Onco404 #Cancer #Kanser #OvarianCancer #MedSky #OncSky #BRCA #BRCAness #Trabectedin #ClinicalTrials
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #BRCAness #HRD #BRCA1 #BRCA2 #PlatinumChemotherapy #PARPInhibitor #TargetedTherapy #Vocabulary
📌 "OncoTerm - Word of the Day" - WEEKLY DIGEST (May 19-25)👋
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #OncoTerm #Oncology #Cancer #Kanser #CancerAwareness #Healthcare #FightCancer #MedSky #OncSky #Vocabulary
📌 “OncoTerm - Günün Kelimesi” - HAFTALIK ÖZET (19-25 Mayıs) 👋
Kansere karşı mücadelede kendimizi bilgiyle güçlendirmek için temel terimleri açıklarken bize katılın.
#Onco404 #OncoTerm #Oncology #Cancer #Kanser #CancerAwareness #Healthcare #FightCancer #Vocabulary
Encorafenib + binimetinib shows strong efficacy, especially in treatment-naïve patients. Genomic-guided triplet therapies need refinement, resistance mechanisms are complex! 🧬
#Onco404 #Cancer #Kanser #Melanoma #TargetedTherapy #ClinicalTrials #BRAF #PrecisionMedicine #MedSky #OncSky
2️⃣ Part II (Triplet Therapy, n=58)
✅ Adding a third agent (ribociclib, capmatinib, etc.) post-progression lacked efficacy (response rates: 2.6% to 0% 🚫), emphasizing the challenge of overcoming resistance.
✅ Safety: Adverse events were manageable and consistent with known safety profiles.
#Onco404
📊 Key Findings
1️⃣ Part I (Encorafenib + Binimetinib)
✅ BRAFi/MEKi-naïve (n=75): Confirmed ORR 73.3% (95% CI, 61.9-82.9). Median PFS 11.1 months.
✅ BRAFi/MEKi-pretreated (n=83): Confirmed ORR 25.3% (95% CI, 16.4-36.0). Median PFS 3.3 months.
#Onco404 #Cancer #Kanser #Melanoma #MedSky #OncSky
This phase II study assessed encorafenib + binimetinib (BRAFi/MEKi), followed by the addition of a third targeted agent based on genomic alterations at progression
@theaacr.bsky.social #CCR
#Onco404 #Cancer #Kanser #Melanoma #TargetedTherapy #ClinicalTrials #BRAF #PrecisionMedicine #MedSky #OncSky
